Major Depression

Neurology
3
Pipeline Programs
7
Companies
8
Clinical Trials
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket

On Market (1)

Approved therapies currently available

U
LAMOTRIGINEApproved
lamotrigine
Unknown Company
Anti-epileptic Agent [EPC]oral2025

Competitive Landscape

6 companies ranked by most advanced pipeline stage

Alliance Pharmaceuticals
3 programs
1
LamotriginePhase 41 trial
CATCH-ITN/A1 trial
functional Near Infrared SpectroscopyN/A1 trial
Active Trials
NCT01893749Completed1,142Est. Jul 2016
NCT01768052Unknown40Est. Jan 2016
NCT00419003Completed26Est. Sep 2008
BrainsWay
BrainsWayJerusalem, Israel
1 program
1
H1 and H2 deep TMS coilsPhase 11 trial
Active Trials
NCT00445237CompletedEst. Mar 2008
Bayer
BayerLEVERKUSEN, Germany
1 program
Clinical examination programN/A1 trial
Active Trials
NCT00260468Completed44Est. Dec 2008
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Longitudinal Study of People Presenting for First Treatment of a Mood DisorderN/A1 trial
Active Trials
NCT01529905Unknown200Est. Jun 2014
J&
Johnson & JohnsonNEW BRUNSWICK, NJ
1 program
Self-help cognitive-behavioral online courseN/A1 trial
Active Trials
NCT01150604Completed547Est. Jun 2013
One Biosciences
One BiosciencesFrance - Paris
1 program
Sleep deprivationN/A1 trial
Active Trials
NCT05497414UnknownEst. Jul 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Alliance PharmaceuticalsLamotrigine
BrainsWayH1 and H2 deep TMS coils
One BiosciencesSleep deprivation
Alliance Pharmaceuticalsfunctional Near Infrared Spectroscopy
Alliance PharmaceuticalsCATCH-IT
Johnson & JohnsonSelf-help cognitive-behavioral online course
BayerClinical examination program
AstraZenecaLongitudinal Study of People Presenting for First Treatment of a Mood Disorder

Clinical Trials (8)

Total enrollment: 1,999 patients across 8 trials

NCT00419003Alliance PharmaceuticalsLamotrigine

Research Study for Major Depressive Disorder: Investigation of Glutamate Medications

Start: Dec 2006Est. completion: Sep 200826 patients
Phase 4Completed
NCT00445237BrainsWayH1 and H2 deep TMS coils

Evaluation of Deep Transcranial Magnetic Stimulation (TMS) H-Coil in the Treatment of Major Depression

Start: May 2006Est. completion: Mar 2008
Phase 1Completed
NCT05497414One BiosciencesSleep deprivation

Neuroimaging Sleep and Mood in Depression

Start: Jan 2022Est. completion: Jul 2024
N/AUnknown
NCT01768052Alliance Pharmaceuticalsfunctional Near Infrared Spectroscopy

Functional Brain Imaging Study of Response to Repetitive TMS (rTMS) Treatment of Major Depression

Start: Jun 2013Est. completion: Jan 201640 patients
N/AUnknown
NCT01893749Alliance PharmaceuticalsCATCH-IT

Primary Care Internet Based Depression Prevention for Adolescents (CATCH-IT) Also Known as Promoting AdolescenT Health

Start: Feb 2012Est. completion: Jul 20161,142 patients
N/ACompleted
NCT01150604Johnson & JohnsonSelf-help cognitive-behavioral online course

Depression Management Project

Start: Jun 2010Est. completion: Jun 2013547 patients
N/ACompleted
NCT00260468BayerClinical examination program

Brain Abnormalities in Late-Onset Major Depression

Start: Nov 2005Est. completion: Dec 200844 patients
N/ACompleted
NCT01529905AstraZenecaLongitudinal Study of People Presenting for First Treatment of a Mood Disorder

Longitudinal Study of People Presenting for First Treatment of a Mood Disorder

Start: Jun 1999Est. completion: Jun 2014200 patients
N/AUnknown

Related Jobs in Neurology

Director, Distribution & Services

Xenon Pharmaceuticals
Remote
11h ago

Senior Medical Science Liaison (NYC Tri-State)

Xenon Pharmaceuticals
Remote
11h ago
$208K - $234K/yr

Director of Medical Affairs

CoMind
Miami, FL
11h ago

Director of Finance

CoMind
London, UK
11h ago

Electronics Engineering Manager

CoMind
London, UK
11h ago

Director of Information Technology

Zavation Medical Products
11h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

7 companies competing in this space

Related Indications

Multiple Sclerosis(274)Schizophrenia(255)Epilepsy(242)Parkinson Disease(171)Alzheimer's Disease(165)Parkinson's Disease(160)Alzheimer Disease(117)Stroke(102)Relapsing-Remitting Multiple Sclerosis(83)Depression(82)